Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10779826 | 0.79 | LMNA (0.47) | ESR2LMNA | |
| SCHEMBL2209017 | 0.75 | MAPT (0.37) | ALDH1A1RAB9AGAAMAPTSMN1; SMN2 | |
| SCHEMBL5670762 | 0.74 | LMNA (0.37) | ALDH1A1RAB9AGAAMAPTSMN1; SMN2 | |
| SCHEMBL16016137 | 0.72 | ALDH1A1 (0.34) | ALDH1A1RAB9AGAAMAPTSMN1; SMN2 | |
| SCHEMBL41691 | 0.72 | ALDH1A1 (0.40) | ALDH1A1RAB9AGAAMAPTESR2 | |
| SCHEMBL24229293 | 0.72 | ESR2 (0.32) | ESR2 | |
| SCHEMBL19595279 | 0.72 | ALDH1A1 (0.34) | ALDH1A1RAB9AGAAMAPTSMN1; SMN2 | |
| SCHEMBL16095310 | 0.72 | ALDH1A1 (0.38) | ALDH1A1RAB9AGAAMAPTSMN1; SMN2 | |
| SCHEMBL23812019 | 0.72 | ESR2 (0.31) | ESR2 | |
| SCHEMBL5615220 | 0.71 | EPHX1 (0.42) | ALDH1A1RAB9AGAAMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10894040-B2 | S1P modulating agents | BIOGEN MA INC. (US) | 2021-01-19 | — | — | US | disclosed |
| US-10894040-B2 | S1P modulating agents | BIOGEN MA INC. (US) | 2021-01-19 | — | — | US | disclosed |
| EP-3660010-A1 | S1P MODULATING AGENTS | Biogen MA Inc. (US) | 2020-06-03 | — | — | EP | disclosed |
| US-20200038385-A1 | S1P MODULATING AGENTS | BIOGEN IDEC MA INC. | 2020-02-06 | — | — | US | disclosed |
| US-20200038385-A1 | S1P MODULATING AGENTS | BIOGEN IDEC MA INC. | 2020-02-06 | — | — | US | disclosed |
| CN-106278999-B | S1P regulator | 比奥根MA公司 | 2019-10-25 | — | — | CN | disclosed |
| EP-3150590-B1 | S1P MODULATING AGENTS | BIOGEN MA INC (US) | 2019-10-16 | — | — | EP | disclosed |
| US-10406144-B2 | SIP modulating agents | BIOGEN MA INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-20180369215-A1 | S1P MODULATING AGENTS | BIOGEN IDEC MA INC. | 2018-12-27 | — | — | US | disclosed |
| US-10034869-B2 | S1P modulating agents | BIOGEN MA INC. (US) | 2018-07-31 | — | — | US | disclosed |
| WO-2006136245-A1 | SUBSTITUTED SPIRO-COMPOUNDS AND THE USE THEREOF FOR PRODUCING MEDICAMENTS | Grünenthal GmbH (DE) | 2006-12-28 | — | — | WO | disclosed |
| EP-1558230-A1 | SPIROCYCLOPROPYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS | Abbott Laboratories (US) | 2005-08-03 | — | — | EP | disclosed |
| US-20040204396-A1 | Spirocyclopropyl amides and acids and their therapeutic applications | ABBVIE INC. | 2004-10-14 | — | — | US | disclosed |
| WO-2004037240-A1 | SPIROCYCLOPROPYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LABORATORIES (US) | 2004-05-06 | — | — | WO | disclosed |
| US-20040077616-A1 | Spirocyclopropyl amides and acids and their therapeutic applications | ABBOTT LABORATORIES | 2004-04-22 | — | — | US | disclosed |
| US-4849574-A | Synthesis of olefins from ketones or aldehydes using bis(alkylchloroalumino)methane | TEXAS ALKYLS, INC. (US) | 1989-07-18 | — | — | US | disclosed |
| EP-0318073-A1 | Synthesis of olefins from ketones using organoaluminium compounds | TEXAS ALKYLS, INC. (US) | 1989-05-31 | — | — | EP | disclosed |
| EP-0316979-A1 | Synthesis of olefins from ketones using a bis(substituted alumino) substituted methane | TEXAS ALKYLS, INC. (US) | 1989-05-24 | — | — | EP | disclosed |
| US-4788367-A | Synthesis of olefins from ketones using bis(alkylchloroalumino)methane | TEXAS ALKYLS INC. (US) | 1988-11-29 | — | — | US | disclosed |
| US-4788368-A | Synthesis of olefins from ketones using a bis(substituted alumino) substituted methane | TEXAS ALKYLS INC. (US) | 1988-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200038385-A1 | S1P MODULATING AGENTS | S1PR2, S1PR1, S1PR3 | ALDH1A1 2452/4885RAB9A 2519/4885GAA 4680/4885 |
| US-20040077616-A1 | Spirocyclopropyl amides and acids and their therapeutic applications | SCN1A, SCN1B, SCN10A | ALDH1A1 85/4885RAB9A 969/4885GAA 1897/4885 |
| US-10034869-B2 | S1P modulating agents | S1PR2, S1PR1, S1PR3 | ALDH1A1 2514/4885RAB9A 1862/4885GAA 4016/4885 |
| US-10406144-B2 | SIP modulating agents | S1PR2, S1PR1, S1PR3 | ALDH1A1 2802/4885RAB9A 2009/4885GAA 4153/4885 |
| US-10894040-B2 | S1P modulating agents | S1PR2, S1PR1, S1PR3 | ALDH1A1 2508/4885RAB9A 1983/4885GAA 4018/4885 |
| US-20180369215-A1 | S1P MODULATING AGENTS | S1PR2, S1PR1, S1PR3 | ALDH1A1 2452/4885RAB9A 2519/4885GAA 4680/4885 |
| US-20040204396-A1 | Spirocyclopropyl amides and acids and their therapeutic applications | SCN1A, SCN1B, SCN10A | ALDH1A1 85/4885RAB9A 969/4885GAA 1897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.